Hypofractionated radiotherapy (RT) combined with dihydroartemisinin (DHA): No synergistic effect observed in a preliminary animal study
Precision Radiation Oncology · 2025-03 · 9 (1) · 54-60
DOI: 10.1002/pro6.70002 ↗Abstract
Abstract Purpose Colorectal cancer (CRC) is one of the leading causes of cancer‐related death worldwide. Dihydroartemisinin (DHA) is an anti‐malaria agent and recent evidence indicates a broad anti‐cancer activity. Radiotherapy (RT) is the cornerstone of cancer treatment and often has synergistic effects when combined with chemotherapy or targeted therapy. We aim to investigate whether synergistic effect exists for RT combined with DHA in a preliminary animal study of CRC treatment. Methods Twenty‐four BALB/c nude mice were subcutaneously injected with 5.0 × 10 6 cells of the murine CRC cell line CT26. When tumor xenografts were formed (∼ 100 mm 3 ), mice were randomly allocated into four groups (n = 6 per group) and the tumor‐bearing mice were intra‐abdominally injected at Day 7, 9, 11 with PBS (control), 6Gy irradiation (RT), DHA (50mg/Kg), and DHA with irradiation (DHA+RT). All RT was performed on a medical linear accelerator using collimated anterior posterior 6MV photon beam conformal to tumor xenografts. The tumor volume was measured using an electronic caliper and was calculated based on the length (L) and the width of the tumor using the formula V = (L x W 2 )/2. Tumor weight was also measured after mice sacrificed. Histological assay was conducted, including using gammaH2AX for DNA double strand breaks (DSB) analysis. Results The tumor weight was 2.4±0.8g, 2.5±0.6g, 0.4±0.2g, and 0.4±0.1g for the control, DHA, RT, and DHA+RT groups, respectively. Significant difference was observed between the control and RT groups, and between the control and DHA+RT groups (p
EUVIMED